Loading...
•
Mar 31, 2025
Dr. Reddy's Q4 2025 Earnings Report
Dr. Reddy's reported solid results with revenue and net income growth driven by strong product launches and the integration of the NRT business.
Key Takeaways
Dr. Reddy’s delivered strong Q4 FY25 performance with 20% revenue growth and 22% increase in net income, fueled by strategic acquisitions and robust sales in key markets.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Dr. Reddy’s anticipates continued momentum supported by new product launches and strategic partnerships, while closely monitoring risks related to pricing pressure and global market volatility.
Positive Outlook
- Strong U.S. product pipeline with 10 ANDA filings and 7 product launches in the quarter.
- Integration of NRT business contributed significantly to revenue.
- Europe saw robust growth with 145% YoY increase driven by NRT and base business.
- Recognition for ESG initiatives and operational excellence.
- Positive regulatory progress including BLA acceptance for biosimilars.
Challenges Ahead
- Gross margin declined YoY due to price erosion and manufacturing leverage.
- Impairment charges related to intangibles in generics business.
- QoQ revenue decline in India and Emerging Markets due to lower volumes.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...